Ophthalmology (corneal graft rejection)
Phase I/II trial preparation


Gene-based treatment for corneal graft rejection

Status: Phase I/II study in preparation

Corneal graft rejection

Cornea grafts are one of the most successful tissue transplants, but over time a significant number are rejected due to corneal neovascularisation. Currently, approximately 100,000 transplants are performed each year, but with this representing only 1% of those requiring treatment the number is predicted to increase substantially. 

Our approach

OXB-202 uses Oxford Biomedica’s LentiVector® platform to genetically modify human donor corneas prior to transplantation.  The modified corneal cells secrete two anti-angiogenic proteins, endostatin and angiostatin, which inhibit neovascularisation and prevent rejection. 

Proof of concept

OXB-202 has achieved impressive proof-of-concept results in an industry standard pre-clinical model of aggressive corneal graft rejection, showing significantly reduced neovascularisation. 

Clinical status

Following the completion of pre-clinical development, Oxford Biomedica working on the regulatory approval for the initiation of a Phase I/II clinical studyin the UK.

Market opportunity

Neovascularisation is an important risk factor for corneal transplant rejection, and therefore a treatment addressing this group of patients has a sizeable market opportunity. Oxford Biomedica’s research indicates a potential market opportunity of between £120 million and £415 million.